UPLOAD Filing
Akari Therapeutics Plc
Date: Jan. 27, 2026 · CIK: 0001541157 · Accession: 0000000000-26-000815
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292930
Letter
January 27, 2026 Abizer Gaslightwala Chief Executive Officer Akari Therapeutics, Plc 401 East Jackson St, Suite 3300 Tampa, FL 33602 Re:Akari Therapeutics, Plc Registration Statement on Form S-1 Filed January 23, 2026 File No. 333-292930 Dear Abizer Gaslightwala: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Win Rutherfurd, Esq.
Show Raw Text
January 27, 2026
Abizer Gaslightwala
Chief Executive Officer
Akari Therapeutics, Plc
401 East Jackson St, Suite 3300
Tampa, FL 33602
Re:Akari Therapeutics, Plc
Registration Statement on Form S-1
Filed January 23, 2026
File No. 333-292930
Dear Abizer Gaslightwala:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Win Rutherfurd, Esq.